GSK plc
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- GSK plc is a British multinational biopharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and specialty therapies focused on respiratory/immunology, oncology, HIV and infectious diseases. Founded through the 2000 merger of Glaxo Wellcome and SmithKline Beecham with origins tracing to 1715, the company is headquartered at 79 New Oxford Street in London, England, and operates globally with manufacturing sites in 37 countries, delivering products to markets including the US, Europe, Asia and emerging regions. Its core portfolio encompasses specialty medicines such as Nucala (mepolizumab) for severe eosinophilic asthma, COPD and CRSwNP; Jemperli (dostarlimab) for endometrial cancer; Blenrep (belantamab mafodotin) for multiple myeloma; Arexvy and Shingrix vaccines for RSV and shingles respectively; a broad range of over 20 vaccines targeting meningococcal disease (e.g. Penmenvy, a 5-in-1 MenABCWY vaccine), HPV, hepatitis and influenza; HIV treatments via ViiV Healthcare including long-acting injectables like Cabenuva (cabotegravir + rilpivirine), Apretude for PrEP and investigational assets like N6LS; general medicines including inhalers for asthma/COPD, antibiotics and gepotidacin (Blujepa) for UTIs; and oncology offerings like Zejula (niraparib) for ovarian cancer. In recent developments, GSK completed the $1.15 billion acquisition of IDRx Inc. in 2025 to advance IDRX-42, a next-generation KIT inhibitor for GIST adding to its GI cancer portfolio; entered a potential $12 billion alliance with Hengrui Pharma paying $500 million upfront for rights to a COPD candidate and up to 11 respiratory, immunology and oncology programs outside greater China; acquired exclusive rights from Syndivia for a prostate cancer antibody-drug conjugate; launched or gained approvals for five new products/line extensions in 2025 including Penmenvy, Blujepa, Nucala for COPD and depemokimab (under FDA/EMA review as the first 6-month ultra-long-acting biologic for type 2 asthma and CRSwNP); announced a $30 billion US investment over five years including a $1.2 billion biologics facility in Pennsylvania; established the GSK-Oxford Cancer Immuno-Prevention Programme; and relocated its headquarters to central London while preparing for CEO transition to Luke Miels in 2026.
Company News
Jefferies backs GSK with 2,500p target after positive lung cancer drug results
GSK lung cancer drug shows 61% response rate in early global trial
Contrasting GSK (NYSE:GSK) and United-Guardian (NASDAQ:UG)
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion
GSK to cut up to 1,217 jobs in Belgium, L'Echo says
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Is the Options Market Predicting a Spike in GSK Plc Stock?
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
GSK: The Gas Pedal Is Finally Down
Contrasting Eyepoint Pharmaceuticals (NASDAQ:EYPT) & GSK (NYSE:GSK)
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
GSK retains ‘buy' rating at Jefferies as B7H3 cancer programme seen as underappreciated
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape